title: New therapy with ASC-J9® to suppress the prostatitis via altering the cytokine CCL2 signals.
abstract: Prostatitis is a common disease contributing to 8% of all urologist visits. Yet the etiology and effective treatment remain to be further elucidated. Using a non-obese diabetes mouse model that can be induced by autoimmune response for the spontaneous development of prostatitis, we found that injection of the ASC-J9® at 75 mg/Kg body weight/48 hours led to significantly suppressed prostatitis that was accompanied with reduction of lymphocyte infiltration with reduced CD4+ T cells in prostate. In vitro studies with a co-culture system also confirmed that ASC-J9® treatment could suppress the CD4+ T cell migration to prostate stromal cells. Mechanisms dissection indicated that ASC-J9® can suppress CD4+ T cell migration via decreasing the cytokine CCL2 in vitro and in vivo, and restoring CCL2 could interrupt the ASC-J9® suppressed CD4+ T cell migration. Together, results from in vivo and in vitro studies suggest that ASC-J9® can suppress prostatitis by altering the autoimmune response induced by CD4+ T cell recruitment, and using ASC-J9® may help us to develop a potential new therapy to battle the prostatitis with little side effects.
authors: George Whipple Laboratory for Cancer Research, Departments of Pathology, Urology, and Radiation Oncology, and Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA.
authors: Shin-Jen
authors: SJ
authors: Lin
authors: George Whipple Laboratory for Cancer Research, Departments of Pathology, Urology, and Radiation Oncology, and Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA.
authors: Fu-Ju
authors: FJ
authors: Chou
authors: George Whipple Laboratory for Cancer Research, Departments of Pathology, Urology, and Radiation Oncology, and Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA.
authors: Chang-Yi
authors: CY
authors: Lin
authors: George Whipple Laboratory for Cancer Research, Departments of Pathology, Urology, and Radiation Oncology, and Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA.
authors: Hong-Chiang
authors: HC
authors: Chang
authors: George Whipple Laboratory for Cancer Research, Departments of Pathology, Urology, and Radiation Oncology, and Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA.
authors: Shuyuan
authors: S
authors: Yeh
authors: George Whipple Laboratory for Cancer Research, Departments of Pathology, Urology, and Radiation Oncology, and Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA.|Sex Hormone Research Center, China Medical University/Hospital, Taichung 404, Taiwan.
authors: Chawnshang
authors: C
authors: Chang
mesh_terms: D000818:Animals; D001327:Autoimmune Diseases / Q000378:metabolism / Q000517:prevention & control; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects; D002460:Cell Line; D002465:Cell Movement / Q000187:drug effects; D018932:Chemokine CCL2 / Q000378:metabolism*; D003474:Curcumin / Q000031:analogs & derivatives* / Q000494:pharmacology; D006801:Humans; D008297:Male; D016688:Mice, Inbred NOD; D011467:Prostate / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D011472:Prostatitis / Q000378:metabolism / Q000517:prevention & control*; D015398:Signal Transduction / Q000187:drug effects*; D017154:Stromal Cells / Q000187:drug effects / Q000378:metabolism
chemical_list: D018932:Chemokine CCL2; D003474:Curcumin; C471106:ASC-J9 compound
keywords: ASC-J9®; CCL2; prostate